Bio Rad实验室 BIO 深 沪
已收盘 02-06 16:00:00 美东时间
301.50
+1.960
+0.65%
华盛通- 最 高307.39
- 今 开301.66
- 成交量 20.17万股
- 最 低 298.35
- 昨 收 299.54
- 总市值 81.33亿
- 52周最高 343.12
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 211.43
- 委 比 -4.76%
- 总股本 2697.48万
- 历史最高 832.70
- 量 比 0.88
- 振 幅 3.02%
- 历史最低 84.02
- 每 手 1
- 风险率 33.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bio-Rad Laboratories Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results
Bio-Rad Laboratories Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results Bio-Rad Laboratories Inc. will announce its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after market close. Management will discuss the results during a conference call s
01-29 21:30
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion
Insight Molecular Diagnostics Inc.在2025年底实现GraftAssure技术全球20个移植中心采用，包括首个加拿大站点，同时GraftAssureDx FDA IVD申请完成95%，计划几周内提交。2026年将加速UK和EU监管申请，并已有17家美国中心参与GraftAssureCore registry。管理层将在2026年1月参加JPM周会议，并计划通过Bio-Rad合作满足移植样本管理需求。
01-05 12:00
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
2025-10-31 02:23
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $265 to $340.
2025-10-30 22:45
CORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.93 by 16.92 percent. This is a 11.88 percent increase over earnings of $2.02 per share from
2025-10-30 05:41
Bio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est
Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a
2025-10-30 04:18
Biome Australia Ltd Announces Virtual Shareholder Meeting
Biome Australia Ltd ( ($AU:BIO) ) has provided an announcement. Biome Australia...
2025-10-24 09:27
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
<p>Biodesix announced an expanded partnership with Bio-Rad to develop and validate in vitro diagnostic assays using ddPCR technology for detecting genomic markers in oncology, starting with the ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer. The assay will enable sensitive detection of ESR1 mutations in ctDNA, aiding the development of targeted therapies and monitoring cancer treatment. Biodesix will manufacture and distribute sp...
2025-10-22 10:17
Biome Australia Achieves Record Sales in Q1 FY26
Biome Australia Ltd ( ($AU:BIO) ) has issued an announcement. Biome Australia L...
2025-10-01 07:47
